<DOC>
	<DOC>NCT02573181</DOC>
	<brief_summary>This study is designed to assess the safety, tolerability, and immunogenicity of V114 compared with Prevnar 13™ in healthy adults 65 years of age or older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.</brief_summary>
	<brief_title>A Study of the Safety, Tolerability, and Immunogenicity of V114 Compared With Prevnar 13™ in Healthy Adults 65 Years of Age or Older Previously Vaccinated With 23-valent Pneumococcal Polysaccharide Vaccine (V114-007)</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Good health; any underlying chronic illness must be documented to be in stable condition Have documented proof of receipt of 23valent pneumococcal polysaccharide vaccine one year or longer prior to study entry. Male, or postmenopausal female Prior administration of any pneumococcal vaccine other than 23valent pneumococcal polysaccharide vaccine History of invasive pneumococcal disease or known history of other culturepositive pneumococcal disease Known hypersensitivity to any vaccine component Known or suspected impairment of immune function Received systemic corticosteroids for &gt;=14 consecutive days and has not completed treatment &lt;=30 days prior to study entry, or received systemic corticosteroids exceeding physiologic replacement doses within 14 days prior to study vaccination Coagulation disorder contraindicating intramuscular vaccination Receives immunosuppressive therapy, including chemotherapeutic agents used to treat cancer or other conditions, and treatments associated with organ or bone marrow transplantation, or autoimmune disease Received a blood transfusion or blood products, including immunoglobulins within the 6 months before receipt of study vaccine or is scheduled to receive a blood transfusion or blood product within 30 days of receipt of study vaccine. Autologous blood transfusions are not considered an exclusion criterion Participated in another clinical study of an investigational product within 2 months before the beginning of or any time during the duration of the current clinical study User of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence.</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>